Retatrutide (GLP-3RT)
Overview
Retatrutide (LY3437943, also known as GLP-3RT in research contexts) is an investigational once-weekly injectable peptide developed by Eli Lilly that acts as a simultaneous agonist at three incretin and glucagon receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GcgR). This triple receptor agonism distinguishes retatrutide from prior generation metabolic peptides including Semaglutide (GLP-1R monoagonist) and Tirzepatide (GLP-1R/GIPR dual agonist), representing the current frontier of incretin pharmacology for obesity and metabolic disease research.
The Phase II clinical trial published in the New England Journal of Medicine by Jastreboff et al. (2023) established retatrutide's weight loss efficacy as the highest reported among any drug class at the time of publication. At the highest dose (12 mg weekly for 48 weeks), participants achieved a mean weight loss of approximately 24% of body weight — substantially exceeding the approximately 15% achieved with tirzepatide and approximately 12% with semaglutide in comparable trial populations. This efficacy signal has generated significant scientific and clinical research interest in retatrutide's mechanism and potential applications.
Retatrutide is currently in Phase III clinical development for obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). It has not yet received regulatory approval from the FDA or any other regulatory body. The compound is available from Alpha Tides under the designation GLP-3RT for research applications.
The mechanistic rationale for triple agonism — combining the appetite suppression and insulin secretion of GLP-1R agonism, the GH-mediated and adipocyte effects of GIPR agonism, and the energy expenditure-promoting glucagonergic activity of GcgR agonism — represents a sophisticated pharmacological design intended to address multiple pathways of energy homeostasis simultaneously.
Research status: Retatrutide has completed Phase II trials with published NEJM data. Phase III trials are ongoing. Not FDA-approved as of this writing. For research use only.
Mechanism of Action
Retatrutide's pharmacological activity derives from simultaneous engagement of three G protein-coupled receptors that regulate glucose homeostasis, appetite, and energy expenditure. Understanding each receptor's contribution is essential for interpreting the compound's clinical pharmacology.
GLP-1 Receptor Agonism
GLP-1R agonism is the most pharmacologically well-characterized component of retatrutide's mechanism, shared with Semaglutide and Tirzepatide. GLP-1R activation in pancreatic beta cells stimulates glucose-dependent insulin secretion and inhibits glucagon release, producing glucose-lowering effects with minimal hypoglycemia risk. Central GLP-1R agonism in hypothalamic and brainstem satiety centers reduces appetite and food intake through multiple mechanisms including delayed gastric emptying, enhanced satiety signaling, and direct action on appetite-regulating neurons in the arcuate nucleus and nucleus tractus solitarius.
GIP Receptor Agonism
GIPR agonism potentiates insulin secretion synergistically with GLP-1R activation and additionally modulates adipocyte function. In adipose tissue, GIPR activation appears to facilitate the redistribution of stored fat and may enhance the thermogenic capacity of adipocytes through cAMP-mediated pathways. The combination of GLP-1R and GIPR agonism, as established in Tirzepatide research, produces greater weight loss than either pathway alone — supporting the pharmacological rationale for polyagonism in metabolic disease treatment.
Glucagon Receptor Agonism
The addition of GcgR agonism in retatrutide is the mechanistic differentiator from dual agonists. GcgR activation in the liver stimulates hepatic glucose production (a hyperglycemic effect that is balanced by concurrent GLP-1R-mediated insulin secretion), promotes hepatic fatty acid oxidation and reduces de novo lipogenesis, and increases energy expenditure through thermogenic effects. In the context of balanced triple agonism, the net glycemic effect is neutral (GLP-1R insulin secretion offsets GcgR-mediated glucose output), while the metabolic and thermogenic effects of glucagonergic signaling contribute additively to the weight loss produced by the appetite-suppressing GLP-1R/GIPR components.
Fatty Acid C18 Modification and Half-Life Extension
Like Semaglutide, retatrutide carries a C18 fatty acid chain modification that enables albumin binding and extends plasma half-life from minutes (for native GLP-1) to approximately 6 days (for retatrutide). This albumin-binding approach is analogous in principle to the DAC technology used in CJC-1295, and similarly transforms the compound from a short-acting peptide into a long-acting once-weekly formulation suitable for clinical use.
Research Studies
Retatrutide's published clinical data set is concentrated in the pivotal Phase II trial and its associated pharmacological characterization studies. The following summaries cover the key publications.
This pivotal Phase II dose-escalation randomized controlled trial enrolled 338 adults with obesity (BMI ≥30) or overweight with comorbidities, randomizing them to retatrutide at doses of 1, 4, 8, or 12 mg weekly, or placebo, over 48 weeks. The primary endpoint was percentage change in body weight at 48 weeks. The 12 mg dose group achieved mean weight loss of approximately 24.2% — the highest efficacy reported for any pharmacological weight loss intervention at the time of publication. All active dose groups significantly outperformed placebo. Secondary endpoints including waist circumference, blood pressure, lipid profiles, and glycemic markers all improved significantly with treatment. The gastrointestinal side effect profile (nausea, vomiting, diarrhea) was consistent with the GLP-1R agonist class but generally mild to moderate in severity.
~24% mean body weight loss at 12 mg · Dose-dependent response · Significant metabolic marker improvementThis preclinical and in vitro characterization study established retatrutide's binding affinities and functional potencies at each of its three receptor targets. The compound demonstrated full agonist activity at GLP-1R and GIPR, and partial agonist activity at GcgR — a profile intentionally designed to capture glucagon receptor metabolic benefits while limiting the hyperglycemic risk of full GcgR agonism. Cellular cAMP accumulation assays confirmed all three receptor activations were present at concentrations achieved during clinical dosing. This study provided the mechanistic foundation for the Phase II clinical trial design.
Full GLP-1R and GIPR agonism · Partial GcgR agonism · cAMP activation confirmed at all three receptorsSecondary endpoint analysis from the Phase II trial examined cardiovascular risk biomarkers in retatrutide-treated subjects. Significant reductions were observed in systolic blood pressure (−5 to −9 mmHg), LDL cholesterol (−20 to −30%), triglycerides (−40 to −50%), and HbA1c in subjects with elevated baseline values. Liver fat fraction, assessed by MRI in a subset of participants, was substantially reduced — consistent with the expected benefit of glucagon receptor-mediated hepatic fat oxidation and lipogenesis suppression. These findings support retatrutide's research potential in NAFLD/NASH beyond its weight loss application.
↓ Blood pressure · ↓ LDL/triglycerides · ↓ Liver fat · ↓ HbA1cWhile head-to-head trials between retatrutide, Tirzepatide, and Semaglutide have not been published at the time of this writing, cross-trial comparison of Phase II/III data suggests a hierarchy of weight loss efficacy: retatrutide (~24%) > tirzepatide (~22%) > semaglutide (~15%) at their respective maximum doses. This progressive improvement with each additional receptor target provides empirical support for the polyagonist pharmacology hypothesis — that broader incretin receptor coverage produces incrementally greater metabolic benefit.
Retatrutide > Tirzepatide > Semaglutide in weight loss efficacy — cross-trial comparisonDosage Research
Important: The following dosage data is sourced from published Phase II clinical trial literature. It is provided for research reference only. Retatrutide is not FDA-approved and all applications are investigational.
Retatrutide dosing in clinical trials uses a dose-escalation schedule to mitigate gastrointestinal side effects, with participants reaching their target maintenance dose over a period of weeks. Once-weekly subcutaneous administration was used throughout the Phase II program.
| Dose Group | Route | Starting Dose | Maintenance Dose | Trial Duration |
|---|---|---|---|---|
| Low dose (Phase II) | Subcutaneous once weekly | 0.5 mg | 1 mg | 48 weeks |
| Mid dose (Phase II) | Subcutaneous once weekly | 0.5 mg | 4 mg | 48 weeks |
| High dose (Phase II) | Subcutaneous once weekly | 0.5 mg | 8 mg | 48 weeks |
| Maximum dose (Phase II) | Subcutaneous once weekly | 0.5 mg | 12 mg | 48 weeks |
All dose groups used a gradual titration schedule starting at 0.5 mg weekly and escalating in 4-week increments to minimize GI side effects. The dose-response relationship was clear across the full range, with the 12 mg dose producing the greatest weight loss and metabolic improvements. GI adverse events (nausea, vomiting, diarrhea) were dose-dependent but generally manageable with the titration schedule.
Use the Alpha Tides Peptide Calculator to perform reconstitution math for research applications.
Half-Life
Retatrutide's half-life has been characterized in human PK studies as part of the Phase II clinical program. The C18 fatty acid albumin-binding modification produces a half-life substantially longer than native GLP-1, enabling once-weekly dosing.
| Parameter | Value | Notes |
|---|---|---|
| Plasma half-life | ~6 days | Enables once-weekly dosing; comparable to Semaglutide (~7 days) |
| Time to steady state | ~4–6 weeks | Steady-state plasma concentrations reached after ~4–6 weekly doses |
| Tmax (SC) | ~24 hours | Peak plasma concentration approximately 1 day post-injection |
| Half-life extension mechanism | Albumin-binding fatty acid (C18) | Same approach as Semaglutide; distinct from DAC technology in CJC-1295 |
Retatrutide's ~6-day half-life positions it in the same pharmacokinetic tier as Semaglutide (~7 days) and Tirzepatide (~5 days), all of which use once-weekly dosing. This class of long-acting peptide hormones has proven clinically practical for patient compliance and metabolic endpoint maintenance.
See the Peptide Half-Life Reference Chart for complete comparisons.
Storage & Stability
Retatrutide is supplied as a lyophilized powder for reconstitution. Storage requirements are consistent with long-chain fatty acid-modified peptides.
| State | Storage Condition | Estimated Stability |
|---|---|---|
| Lyophilized (unreconstituted) | −20°C, protected from light | 24+ months |
| Lyophilized (unreconstituted) | 2–8°C, protected from light | 3–6 months |
| Reconstituted in BAC water | 2–8°C, protected from light | 4–6 weeks |
| Reconstituted — avoid | Room temperature or above | Rapid degradation |
Key Handling Notes
- Store lyophilized retatrutide at −20°C in sealed vials, protected from light and moisture.
- The fatty acid modification does not require special handling precautions beyond standard peptide storage.
- Once reconstituted in bacteriostatic water, refrigerate at 2–8°C and use within 4–6 weeks.
- Do not freeze reconstituted solution.
- Use aseptic technique at all times during reconstitution and handling.
See the full Peptide Reconstitution Protocol for complete laboratory procedures.
Summary
Retatrutide represents the current leading edge of incretin receptor pharmacology, combining GLP-1R, GIPR, and GcgR agonism into a single once-weekly peptide that, in Phase II trials, produced the highest weight loss efficacy reported for any drug in the obesity literature at the time of publication. The ~24% mean body weight reduction at the 12 mg dose — compared to ~15% for Semaglutide and ~22% for Tirzepatide — provides strong empirical validation for the polyagonist pharmacology hypothesis.
The mechanistic rationale is well-grounded: each of the three receptor targets contributes a distinct and complementary metabolic effect (insulin secretion, appetite suppression, and hepatic/adipocyte fat metabolism from GLP-1R; adipocyte modulation and insulin sensitization from GIPR; hepatic fat oxidation and thermogenesis from GcgR), and the balanced activity profile — including partial rather than full GcgR agonism to limit hyperglycemia risk — reflects sophisticated pharmaceutical optimization.
Phase III trials are ongoing and will provide the larger-scale efficacy and safety data necessary for regulatory submission. The secondary endpoints from Phase II — substantial improvements in blood pressure, lipid profiles, and liver fat — suggest research utility in cardiovascular risk reduction and NAFLD/NASH beyond obesity treatment, expanding the potential scope of retatrutide's eventual research and clinical applications.
For researchers studying metabolic pathways, retatrutide's triple receptor pharmacology provides a uniquely rich research model for examining the differential contributions of GLP-1R, GIPR, and GcgR signaling to metabolic outcomes — contributions that can be isolated through comparison with monoagonist and dual agonist compounds from the same pharmacological class.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389(6):514–526. PMID: 37366315. PubMed →
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. "The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity." Diabetes Obes Metab. 2021;23(3):754–762. PMID: 33982773. PubMed →
- Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021;385(6):503–515. PMID: 34170647. PubMed →
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989–1002. PMID: 33567185. PubMed →
- Nauck MA, Quast DR, Wefers J, Meier JJ. "GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art." Mol Metab. 2021;46:101102. PMID: 33248299. PubMed →
- Holst JJ, Gribble F, Horowitz M, Rayner CK. "Roles of the Gut in Glucose Homeostasis." Diabetes Care. 2016;39(6):884–892. PMID: 27222549. PubMed →
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205–216. PMID: 35658024. PubMed →